---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-005908"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2023-08-18T23:59:59+00:00"
generated_at: "2026-06-11T06:58:28.073437+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CNS Pharma receives Nasdaq delisting notice for failure to meet $2.5M equity requirement

## Summary
- Nasdaq notified CNS Pharma on Aug 17, 2023 of non-compliance with $2.5M stockholders' equity minimum (Rule 5550(b)(1)).
- Company also does not meet alternatives of market value of listed securities or net income from continuing operations.
- No immediate delisting; company has 45 calendar days to submit a plan. Nasdaq may grant up to 180-day extension if plan accepted.
- If plan rejected, company may appeal to Nasdaq Hearings Panel; no assurance of success.

## SEC filing metadata
- accession: 0001683168-23-005908
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2023-08-18T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316823005908/0001683168-23-005908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316823005908/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-005908
- JSON: https://secwatch.observer/filing/0001683168-23-005908.json
- Plain text: https://secwatch.observer/filing/0001683168-23-005908.txt

## Key facts
- Listing & Compliance Notices
  CNS Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: August 17, 2023, CNS Pharmaceuticals, Inc. (the “Company”) received a letter (the “Letter”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), which notified the Company that it does not presently comply with Nasdaq’s Listing Rule 5550(b)(1) (the “Listing Rule”), which requires that the Company maintain a minimum of $2.5 million in stockholders’ equity, and that the Company also does not meet the alternatives of market value of listed securities or net income from continuing operations set forth in the Listing Rule. The Letter does
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316823005908/0001683168-23-005908-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.